A uncommon childhood illness with no authorized remedy could have an surprising new therapeutic candidate.
Sildenafil, the energetic ingredient additionally bought beneath the model title Viagra, could assist scale back signs in folks with Leigh syndrome. Researchers report this discovering within the journal Cell. The research was led by scientists at Charité – Universitätsmedizin Berlin in collaboration with groups from Heinrich Heine College Düsseldorf (HHU), College Hospital Düsseldorf (UKD), and the Fraunhofer Institute for Translational Medication and Pharmacology ITMP in Hamburg.
Leigh syndrome is a uncommon metabolic dysfunction that begins in childhood and causes extreme neurological and muscular issues. The illness has lengthy been thought of untreatable. In a pilot research involving six sufferers, sildenafil appeared to sluggish or enhance elements of the situation.
The dysfunction is congenital and impacts each the mind and muscle groups as a result of cells can’t correctly produce vitality. Signs usually seem in infancy or early childhood and step by step worsen. Sufferers could develop epileptic seizures, muscle weak point, and paralysis. Cognitive growth will also be affected. Individuals with Leigh syndrome normally have a a lot shorter life expectancy, and there are at present no authorized drugs to deal with the illness.
A real shock: Efficiency drug proves efficient
Researchers just lately recognized an surprising drug candidate that produced promising leads to an early research: sildenafil, a medicine categorised as a PDE-5 inhibitor. The drug is extensively often called a remedy for erectile dysfunction in adults. As a result of it relaxes blood vessels, it is usually used to deal with pulmonary hypertension in infants.
Within the research, six folks with Leigh syndrome between the ages of 9 months and 38 years acquired steady sildenafil remedy. Inside a couple of months, the sufferers confirmed noticeable enhancements in muscle power. Some additionally skilled a discount or disappearance of neurological signs.
Sufferers additionally recovered sooner from metabolic crises. These episodes happen when vitality metabolism turns into overwhelmed, which might quickly worsen the illness.
“For instance, within the case of a kid present process sildenafil remedy, the strolling distance elevated tenfold, from 500 to five,000 meters (about 0.31 to three.1 miles),” as Prof. Markus Schuelke explains. “In one other youngster, the remedy fully suppressed metabolic crises that occurred virtually month-to-month, whereas one other affected person now not suffered from epileptic seizures.”
Schuelke is a doctor and scientist at Charité’s Division of Pediatric Neurology and one of many research’s lead authors.
“Such results considerably enhance the standard of lifetime of Leigh syndrome sufferers. Whereas we must affirm these preliminary observations in a extra complete research, we’re very happy to have discovered a promising drug candidate for the remedy of this critical hereditary illness.”
Why the seek for therapies for uncommon illnesses is tough
Advances like this aren’t straightforward to realize as a result of Leigh syndrome is extraordinarily uncommon. The situation impacts about one in 36,000 kids.
“The low case numbers make it tough to analysis the illness and current some obstacles in our pressing seek for efficient therapies,” explains Markus Schuelke.
With so few sufferers, giant scientific trials are tough to conduct. Researchers should usually collaborate throughout a number of medical facilities around the globe. One other limitation is that scientists can’t merely take away mind or nerve tissue from sufferers to research the illness.
To seek for potential remedies, the analysis staff used an revolutionary laboratory technique.
First, they collected pores and skin cells from sufferers and reprogrammed them into induced pluripotent stem cells within the lab. These cells can grow to be many alternative cell sorts. The scientists then used them to supply nerve cells that confirmed the identical metabolic defects present in Leigh syndrome.
Subsequent, the staff screened greater than 5,500 compounds. These included medicine already authorized for different illnesses in addition to substances with intensive security and efficacy knowledge. Every compound was examined to see whether or not it may enhance the perform of the lab grown nerve cells.
Optimistic impact on cells, in animal fashions, and in sufferers
“That is the biggest drug screening for the remedy of Leigh syndrome up to now,” emphasizes Dr. Ole Pless, lead creator of the research from ITMP. “It confirmed that sildenafil, amongst different medicine, improved {the electrical} performance of the nerve cells.”
Additional experiments confirmed these outcomes. In three dimensional miniature mind fashions referred to as organoids, sildenafil stimulated the expansion of nerve cells. The drug additionally improved vitality metabolism and prolonged life span in animal fashions.
“Primarily based on these outcomes, we determined to manage the drug as a part of a person therapeutic trial in six sufferers with Leigh syndrome,” as Prof. Alessandro Prigione, lead creator from the Division of Basic Pediatrics, Neonatology, and Pediatric Cardiology on the UKD acknowledged.
“One other decisive issue was the truth that detailed security knowledge was accessible for the long run use of sildenafil in kids, because the energetic ingredient is already authorized for different pediatric problems.”
The primary affected person was handled at Charité. After encouraging outcomes, extra sufferers acquired the remedy in Düsseldorf, Munich, and Bologna. Total, the remedy was nicely tolerated.
Complete scientific research deliberate
Following publication of the outcomes, the European Medicines Company (EMA) granted sildenafil orphan drug standing (ODD), which is used for drugs developed to deal with uncommon illnesses.
This designation permits a simplified approval pathway to assist speed up new remedies. To verify the findings and probably assist approval of sildenafil for Leigh syndrome, researchers are planning a Europe broad placebo managed scientific trial. The research might be carried out as a part of the SIMPATHIC EU challenge.
Reference: “Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial illness remedy” by Annika Zink, Dao-Fu Dai, Annika Wittich, Marie-Thérèse Henke, Giulia Pedrotti, Sonja Heiduschka, Guillem Santamaria, Tancredi Massimo Pentimalli, Christian Brueser, Sofia Notopoulou, Abdul Rahim Umar, Aleksandra Zhaivoron, Laura Petersilie, Caleb Jerred, Jesper Bergmans, Louis Anton Neu, Fabian Schumacher, Jan Keller-Findeisen, Agnieszka Rybak-Wolf, Daniel Stach, Jeanette Reinshagen, Undine Haferkamp, Kim Krieg, Andrea Zaliani, Liliya Euro, Alessia Di Donfrancesco, Chiara Santanatoglia, Enrica Cappellozza, Marta Suarez Cubero, Mario Pavez-Giani, Oleh Bakumenko, David Meierhofer, Alan Foley, Susanne Morales-Gonzalez, Isabella Tolle, Diran Herebian, Daniele Bonesso, Giulia Cecchetto, Sakurako Nagumo Wong, Monica Moresco, Alessandra Maresca, Ilaria Decimo, Francesco De Sanctis, Annalisa Adamo, Merel J.W. Adjobo-Hermans, Roberto Duchi, Maria Barandalla, Marco Scaglia, Andrea Perota, Cesare Galli, Burkhard Kleuser, Lukas Cyganek, Chris Mühlhausen, Lars Schlotawa, Valeria Tiranti, Ertan Mayatepek, Ildiko Szabo, Chiara La Morgia, Thomas Klopstock, Valerio Carelli, Felix Distelmaier, Andrea Rossi, Nikolaus Rajewsky, Ghanim Ullah, Stefan Jakobs, Christine R. Rose, Spyros Petrakis, Frank Edenhofer, Werner J.H. Koopman, Pawel Lisowski, Anu Suomalainen, Dario Brunetti, Antonio del Sol, Emanuela Bottani, Ole Pless, Markus Schuelke and Alessandro Prigione, 11 March 2026, Cell.
DOI: 10.1016/j.cell.2026.02.008
